Long QTc interval and torsade de pointes caused by fluconazole

Annals of Pharmacotherapy

Volumn 40, Issue 7-8, 2006, Pages 1456-1461

  Pham, C Phu ^a   De Feiter, Peter W ^b   Van Der Kuy, P Hugo M ^b   Van Mook, Walther N K A ^b  

^a TWENTEBORG HOSPITAL   (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Candida pneumonia; Domperidone; Fluconazole; QTc interval; Systemic lupus erythematosus; Torsade de pointes

Indexed keywords

CYTOCHROME P450; DOMPERIDONE; FLUCONAZOLE; ISOPRENALINE; MAGNESIUM;

ADULT; ARTICLE; CANDIDA ALBICANS; CASE REPORT; DRUG DOSE REGIMEN; DRUG WITHDRAWAL; FEMALE; HUMAN; KIDNEY DYSFUNCTION; NARANJO SCALE; PNEUMONIA; PRIORITY JOURNAL; QT PROLONGATION; RATING SCALE; RESPIRATORY FAILURE; RISK ASSESSMENT; RISK FACTOR; SYSTEMIC LUPUS ERYTHEMATOSUS; TORSADE DES POINTES;

ADULT; ANTIFUNGAL AGENTS; BRONCHOALVEOLAR LAVAGE FLUID; CANDIDIASIS; DOMPERIDONE; FEMALE; FLUCONAZOLE; HUMANS; LONG QT SYNDROME; PNEUMONIA; TORSADES DE POINTES;

EID: 33746961164     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1G741     Document Type: Article

References (31)

1. Viskin S. Long QT syndromes and torsade de pointes. Lancet 1999;354: 1625-33.
2. Roden DM. A practical approach to torsade de pointes. Clin Cardiol 1997;20:285-90.
3. De Ponti F, Poluzzi E, Montanaro N. QT-interval prolongation by noncardiac drugs: lessons to be learned from recent experience. Eur J Clin Pharmacol 2000;56:1-18.
4. Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med 2004;350:1013-22.
5. Gandhi PJ, Menezes PA, Vu HT, Rivera AL, Ramaswamy K. Fluconazole- and levofloxacin-induced torsades de pointes in an intensive care unit patient. Am J Health Syst Pharm 2003;60:2479-83.
6. Dorsey ST, Biblo LA. Prolonged QT interval and torsades de pointes caused by the combination of fluconazole and amitriptyline. Am J Emerg Med 2000;18:227-9.
7. Hrovatin E, Zardo F, Brieda M, et al. [Long QT and torsade de pointes in a patient with acquired human immunodeficiency virus infection in multitherapy with drugs affecting cytochrome P450] Italian. Ital Heart J Suppl 2004;5:735-40.
8. Khazan M, Mathis AS. Probable case of torsades de pointes induced by fluconazole. Pharmacotherapy 2002;22:1632-7.
9. Wassmann S, Nickenig G, Bohm M. Long QT syndrome and torsade de pointes in a patient receiving fluconazole. Ann Intern Med 1999;131:797.
10. Tholakanahalli VN, Potti A, Hanley JF, Merliss AD. Fluconazole-induced torsade de pointes. Ann Pharmacother 2001;35:432-4. DOI 10.1345/aph.10210
11. Malik M, Farbom P, Batchvarov V, Hnatkova K, Camm AJ. Relation between QT and RR intervals is highly individual among healthy subjects: implications for heart rate correction of the QT interval. Heart 2002; 87:220-8.
12. Vincent GM, Timothy KW, Leppert M, Keating M. The spectrum of symptoms and QT intervals in carriers of the gene for the long-QT syndrome. N Engl J Med 1992;327:846-52.
13. Al-Khatib SM, LaPointe NM, Kramer JM, Califf RM. What clinicians should know about the QT interval. JAMA 2003;289:2120-7.
14. Priori SG, Schwartz PJ, Napolitano C, et al. Risk stratification in the long-QT syndrome. N Engl J Med 2003;348:1866-74.
15. Cameron HA, Reyntjens AJ, Lake-Bakaar G. Cardiac arrest after treatment with intravenous domperidone (letter). Br Med J (Clin Res Ed) 1985;290:160.
16. Quinn N, Parkes D, Jackson G, Upward J. Cardiotoxicity of domperidone (letter). Lancet 1985;2:724.
17. Osborne RJ, Slevin ML, Hunter RW, Hamer J. Cardiotoxicity of intravenous domperidone (letter). Lancet 1985;2:385.
18. Roussak JB, Carey P, Parry H. Cardiac arrest after treatment with intravenous domperidone. Br Med J (Clin Res Ed) 1984;289:1579.
19. Giaccone G, Bertetto O, Calciati A. Two sudden deaths during prophylactic antiemetic treatment with high doses of domperidone and methylprednisolone. Lancet 1984;2:1336-7.
20. Joss RA, Goldhirsch A, Brunner KW, Galeazzi RL. Sudden death in cancer patient on high-dose domperidone (letter). Lancet 1982;1:1019.
21. Pohjola-Sintonen S, Viitasalo M, Toivonen L, Neuvonen P. Itraconazole prevents terfenadine metabolism and increases risk of torsades de pointes ventricular tachycardia. Eur J Clin Pharmacol 1993;45:191-3.
22. Honig PK, Wortham DC, Zamani K, Conner DP, Mullin JC, Cantilena LR. Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences. JAMA 1993;269:1513-8.
23. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
24. Nicolau DP, Crowe H, Nightingale CH, Quintiliani R. Effect of continuous arteriovenous hemodiafiltration on the pharmacokinetics of fluconazole. Pharmacotherapy 1994;14:502-5.
25. Bergner R, Hoffmann M, Riedel KD, et al. Fluconazole dosing in continuous veno-venous haemofiltration (CWHF): need for a high daily dose of 800 mg. Nephrol Dial Transplant 2006;21:1019-23. Epub 2005 Nov 25
26. Viskin S, Justo D, Halkin A, Zeltser D. Long QT syndrome caused by noncardiac drugs. Prog Cardiovasc Dis 2003;45:415-27.
27. Haverkamp W, Monnig G, Schulze-Bahr E, Haverkamp F, Breithardt G. Physician-induced torsade de pointes-therapeutic implications. Cardiovasc Drugs Ther 2002;16:101-9.
28. Makkar RR, Fromm BS, Steinman RT, Meissner MD, Lehmann MH. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. JAMA 1993;270:2590-7.
29. Lindgren A, Wohlfart B, Pahlm O, Johansson BB. Electrocardiographic changes in stroke patients without primary heart disease. Clin Physiol 1994; 14:223-31.
30. Afsar N, Fak AS, Metzger JT, Van Melle G, Kappenberger L, Bogousslavsky J. Acute stroke increases QT dispersion in patients without known cardiac diseases. Arch Neurol 2003;60:346-50.
31. Lazzerini PE, Acampa M, Guideri F, et al. Prolongation of the corrected QT interval in adult patients with anti-Ro/SSA-positive connective tissue diseases. Arthritis Rheum 2004;50:1248-52.